Peapod Lane Capital LLC Invests $550,000 in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Peapod Lane Capital LLC bought a new stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 227,239 shares of the biotechnology company’s stock, valued at approximately $550,000. Peapod Lane Capital LLC owned approximately 0.56% of Oramed Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ORMP. XTX Topco Ltd raised its stake in Oramed Pharmaceuticals by 59.7% in the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 9,242 shares during the period. Marquette Asset Management LLC acquired a new position in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $81,000. Dimensional Fund Advisors LP increased its holdings in shares of Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 10,774 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Oramed Pharmaceuticals in the 3rd quarter valued at $272,000. Finally, Murchinson Ltd. lifted its holdings in Oramed Pharmaceuticals by 0.5% during the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after purchasing an additional 8,889 shares during the last quarter. 12.73% of the stock is owned by institutional investors.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $2.47 on Thursday. The business’s 50 day simple moving average is $2.35 and its 200 day simple moving average is $2.37. Oramed Pharmaceuticals Inc. has a 1 year low of $2.00 and a 1 year high of $3.67. The company has a market capitalization of $99.57 million, a P/E ratio of 22.45 and a beta of 1.66.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, February 6th.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.